Abivax, founded by Philippe Pouletty, M.D. (Truffle Capital) in 2013, is a late clinical-stage BioTech company focused on developing therapies for chronic inflammatory diseases. Their leading drug candidate, Obefazimod, designed to treat Ulcerative Colitis (UC) has published its positive Phase III results in July 2025. As a result, Abivax is now the #1 Biotech in Europe and #3 Worldwide and its stock price increased +1700% in 2025!